Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00250458 | Study to Test a Marketed Product in the Treatment of Migraine-associated Nausea | PHASE3 | COMPLETED | 346 | — | — | Mar 1, 2006 | Oct 1, 2006 | Feb 3, 2022 | - | — |
Participants reporting the absence of nausea at 2 hours post treatment. Absence or presence of nausea was recorded by the participants in an electronic diary. Absence is defined as no nausea at 2 hours post-treatment.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Rizatriptan (MK0462)10 mg orally disintegrating tablet/oral lyophilisate |
| 2 | PLACEBO_COMPARATOR | matching placebo |
| Name | Type | Description |
|---|---|---|
| Comparator: Rizatriptan | DRUG | One dose Rizatriptan 10 mg orally disintegrating tablet / oral lyophilisate to treat one migraine attack. |
| Comparator: Placebo | DRUG | One dose matching placebo to Rizatriptan to treat one migraine attack. |
Inclusion Criteria: * 6-month history of migraine, moderate to severe migraine attacks with nausea, 1-6 migraine attacks per month Exclusion Criteria: * Heart disease, high blood pressure
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 15 | PHASE3 | Atogepant, Topiramate, Ubrogepant, MEDI0618 |
| Pfizer Inc. | PFE | 9 | PHASE3 | Rimegepant, Rimegepant/BHV3000, Zavegepant, Various, Rimegepant for acute migraine treatment |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Galcanezumab |
| Amgen Inc. | AMGN | 2 | PHASE3 | Erenumab Dose 1, erenumab-aooe |
| Ki Health Partners. LLC | RVNC | 1 | — | Daxibotulinumtonix A |